Substrate Ablation Guided by High Density Mapping in Atrial Fibrillation
NCT ID: NCT02093949
Last Updated: 2017-11-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
152 participants
OBSERVATIONAL
2013-09-30
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This substrate ablation method is performed routinely in the centers involved in the study so, patients were not assigned by the investigators to undergo a specific procedure because of the study, in all cases patient would have beneficiate from this substrate mapping ablation method.
We assessed procedural and follow up outcomes of this subatrate ablation group and compared them with an historical control group undergoing conventional ablation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Studied
Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation
Routine substrate ablation without pulmonary vein Isolation
Control
The validation set included a cohort of 47 patients with symptomatic drug-refractory AF who underwent ablation using a conventional approach.
Routine conventional ablation with pulmonary vein Isolation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Routine substrate ablation without pulmonary vein Isolation
Routine conventional ablation with pulmonary vein Isolation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital St. Joseph, Marseille, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
SEITZ JULIEN
MD , Cardiologist Rythmologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julien Seitz, MD
Role: PRINCIPAL_INVESTIGATOR
St Joseph hospital Marseille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Saint Joseph
Marseille, , France
CHU
Nice, , France
Institut Mutualiste de Montsouris
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Seitz J, Bars C, Theodore G, Beurtheret S, Lellouche N, Bremondy M, Ferracci A, Faure J, Penaranda G, Yamazaki M, Avula UM, Curel L, Siame S, Berenfeld O, Pisapia A, Kalifa J. AF Ablation Guided by Spatiotemporal Electrogram Dispersion Without Pulmonary Vein Isolation: A Wholly Patient-Tailored Approach. J Am Coll Cardiol. 2017 Jan 24;69(3):303-321. doi: 10.1016/j.jacc.2016.10.065.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SUBSTRATE-HD
Identifier Type: -
Identifier Source: org_study_id